Cofactor Genomics Names Chris Parker CEO to Lead Expansion of Medicare-Approved OncoPrism
Cofactor Genomics Welcomes Chris Parker as CEO
Cofactor Genomics, a leader in precision medicine, has appointed Chris Parker as the new CEO and a member of the Board. With his extensive experience in biotechnology and diagnostics, Parker is set to steer the company towards its ambitious goals. His leadership comes at a pivotal time as Cofactor seeks to expand its impact in immunotherapy.
Founder Jarret Glasscock Takes on New Roles
Jarret Glasscock, the founder and former CEO of Cofactor Genomics, is transitioning to serve as the company’s President and Chief Technology Officer (CTO). In addition to his new roles, Glasscock will remain a vital part of the Board of Directors. His deep expertise in genomics and innovation will continue to drive Cofactor’s technological advancements.
Strategic Focus on Precision Immunotherapy
Under the new leadership, Cofactor Genomics will intensify its efforts to make precision medicine more accessible in the field of immunotherapy. The company aims to enhance its OncoPrism test, which identifies cancer patients who could benefit from immune checkpoint inhibitor therapies. This strategic focus aligns with Cofactor’s mission to bridge the precision medicine gap.
Chris Parker Brings Decades of Experience
Chris Parker joins Cofactor Genomics with nearly thirty years of experience in the biotechnology and diagnostics industries. His previous roles at Affymetrix, Cellular Dynamics, and Exact Sciences have equipped him with the skills to lead Cofactor’s commercialization efforts. Parker’s track record of bringing breakthrough technologies to market is expected to propel Cofactor’s growth.
Cofactor’s Recent Milestones and Achievements
In 2024, Cofactor achieved significant milestones, including Medicare coverage of its OncoPrism test for head and neck cancer patients. The company also completed clinical validations in non-small cell lung cancer and published impressive results from its PREDAPT clinical trial. These achievements underscore the effectiveness of Cofactor’s RNA-based precision medicine solutions.
Conclusion
The leadership changes at Cofactor Genomics mark a new chapter in the company’s journey towards advancing precision medicine in oncology. With Chris Parker at the helm and Jarret Glasscock driving technological innovation, Cofactor is well-positioned to expand its reach and make a meaningful impact on cancer treatment. The company’s continued focus on clinical excellence and commercialization promises a brighter future for patients in need.
Read the full article here:
venturebeat.com